Keywords: Dendreon, Provenge, EU filing, USA commercialization,m Prostate cancer, DN24-02 ind, Bladder cancer

Dendreon shares rise on plans to gain EU marketing approval for Provenge and US commercialization

Article | 10 January 2011

Print This

US biotech firm Dendreon (Nasdaq: DNDN) saw its shares rise 4.2% to $36.90 in early trading last Friday, after the company outlined ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in